secwatch.observer — SEC 8-K summary
======================================

Issuer:     HCW Biologics Inc. (HCWB)
CIK:        0001828673
Form:       8-K
Filed at:   2026-07-29T21:12:42+00:00
Accession:  0001493152-26-035233
Event type: other_material
Sentiment:  neutral
Materiality: 0.60
Item codes: 1.01, 3.02, 7.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

HCW Biologics prices $1.6M private placement of units with pre-funded and common warrants
--------------------------------------------------------------------------------

- Issued 618,682 units at $2.585 per unit; includes 218,682 shares and 400,000 pre-funded warrants.
- Gross proceeds of $1.6M; net proceeds for clinical trials (HCW9302, HCW11-018b, HCW11-040) and working capital.
- CEO Hing C. Wong, Chairman Scott Garrett, and SVP Lee Flowers participated on same terms as other investors.
- Common warrants for up to 618,682 shares require stockholder approval under Nasdaq Rule 5635(d).
- Pre-funded warrants exercisable at $0.0001; common warrants at $2.585, expire 5.5 years from issuance.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1828673/000149315226035233/0001493152-26-035233-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1828673/000149315226035233/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001493152-26-035233

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer